

PRESS RELEASE

Stockholm, Sweden, 6 July 2020



Invitation – Presentation of Sobi's Q2 2020 results

On 16 July, at 08:00 CET, [Swedish Orphan Biovitrum AB \(publ\)](#) (Sobi™) will publish its report for the second quarter 2020. Investors, financial analysts and media are invited to participate in a telephone conference, which will include a presentation of the results, on the same day at 13:00 CEST. The event will be hosted by Sobi's CEO and President, Guido Oelkers, and the presentation will be held in English.

The presentation can be followed live, or afterwards on www.sobi.com. Slides used in the presentation will be made available on Sobi's website prior to the telephone conference.

To participate in the telephone conference, please call:

SE: +46 8 505 583 54

UK: +44 333 300 9274

US: +1 646 722 4903

[Click here to go to the live webcast.](#)

After the live event the webcast will be available on-demand via the same link.

About Sobi™

Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Sobi is providing sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. Today, Sobi employs approximately 1,400 people across Europe, North America, the Middle East, Russia and North Africa. In 2019, Sobi's revenue amounted to SEK 14.2 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi at www.sobi.com.

For more information please contact

Paula Treutiger, Head of Communication & Investor Relations

+ 46 733 666 599

paula.treutiger@sobi.com

Linda Holmström, Corporate Communication & Investor Relations

+ 46 708 734 095

linda.holmstrom@sobi.com

Swedish Orphan Biovitrum AB (publ)

Postal address SE-112 76 Stockholm, Sweden

Phone: +46 8 697 20 00 | www.sobi.com